COVID-19 in an Adult with Down Syndrome: Impact on Autoimmune Response
Author(s) -
Hiroshi Kobayashi,
Mana Akiniwa,
Yoshiko Yamaguchi,
Yuji Hirai,
Akiko Aoki
Publication year - 2022
Publication title -
case reports in infectious diseases
Language(s) - English
Resource type - Journals
eISSN - 2090-6633
pISSN - 2090-6625
DOI - 10.1155/2022/6128496
Subject(s) - medicine , serositis , leukocytopenia , immunology , autoantibody , pneumonia , disease , covid-19 , population , autoimmunity , autoimmune disease , infectious disease (medical specialty) , antibody , chemotherapy , environmental health
We here report a case of COVID-19 with effusion prior to the development of pneumonia in an adult with Down syndrome. Serositis due to rheumatic disease was initially suspected because of a high titer of serum autoantibodies and leukocytopenia; however, SARS-CoV-2 infection was confirmed by reverse transcription polymerase chain reaction on admission after previous negative tests. Several cases of COVID-19 have been associated with autoimmune responses along with some cases of COVID-19 with autoimmune manifestations. Furthermore, patients with Down syndrome have a higher mortality risk from COVID-19 than the general population, and it is believed that a high sensitivity to the interferon response may contribute to the increased severity of the disease. Thus, careful attention should be paid to autoimmune manifestations due to SARS-CoV-2 infection for ensuring a proper and timely diagnosis, especially in patients with Down syndrome.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom